← Back to Clinical Trials
Recruiting NCT04432025

NCT04432025 Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04432025
Status Recruiting
Phase
Sponsor Imperial College London
Condition Obesity
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2021-04-01
Primary Completion 2027-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Bariatric surgery + goal directed medical therapyBariatric surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2021-04-01 with a primary completion date of 2027-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

Eligibility Criteria

Inclusion Criteria: * eligible for bariatric surgery according to NICE guidelines (GC 189) * Type 2 diabetes mellitus * BMI \>30kg/m2 Exclusion Criteria: * Recent hospitalisation in the past 30 days * Recurrent hypoglycaemic episodes * Recurrent hypotensive episodes * Contraindications to bariatric surgery * Previous bariatric surgery * Current pregnancy * Breastfeeding

Contact & Investigator

Central Contact

Alexander Miras, MRCP

✉ a.miras@nhs.net

📞 : +44 (0)20 8383 3242

Frequently Asked Questions

Who can join the NCT04432025 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04432025 currently recruiting?

Yes, NCT04432025 is actively recruiting participants. Contact the research team at a.miras@nhs.net for enrollment information.

Where is the NCT04432025 trial being conducted?

This trial is being conducted at Dublin, Ireland.

Who is sponsoring the NCT04432025 clinical trial?

NCT04432025 is sponsored by Imperial College London. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology